Holen Sie sich die Stockscreener-App
89.83
0.74%
-0.67
Handel nachbörslich:
90.00
0.17
+0.19%
Schlusskurs vom Vortag:
$90.50
Offen:
$89.83
24-Stunden-Volumen:
145.42K
Relative Volume:
0.69
Marktkapitalisierung:
$1.32B
Einnahmen:
$1.30M
Nettoeinkommen (Verlust:
$-130.19M
KGV:
-10.71
EPS:
-8.3898
Netto-Cashflow:
$-131.94M
1W Leistung:
-5.45%
1M Leistung:
-11.73%
6M Leistung:
+8.09%
1J Leistung:
+145.47%
1-Tages-Spanne:
$87.72
$90.72
1-Wochen-Bereich:
$83.61
$96.10
52-Wochen-Spanne:
$28.16
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
89.83 | 1.32B | 1.30M | -130.19M | -131.94M | -8.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-04-08 | Eingeleitet | Stifel | Buy |
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Two CEO-linked trusts buy 10,040 Inhibrx Biosciences (INBX) shares; no trading plan is reported. - Stock Titan
Inhibrx Biosciences stock falls 1.62 percent on October 5 - AD HOC NEWS
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com - Investing.com Nigeria
Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock - Investing.com Canada
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com - Investing.com India
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com - Investing.com UK
Four purchases over two days: Inhibrx Biosciences (INBX) CEO's family trust bought 10,000 shares. - Stock Titan
Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock - Investing.com
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock By Investing.com - Investing.com Nigeria
Form 4 Inhibrx Biosciences Inc For: 23 September - Investing.com India
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock - Investing.com India
Form 4 Inhibrx Biosciences Inc For: 23 September By Investing.com - Investing.com UK
At $100 a share, a director's family trust bought 5,000 shares of Inhibrx Biosciences (INBX). - Stock Titan
Inhibrx Biosciences Director Kristiina Vuori Receives Corrected Stock Option Grant - Kalkine Media
Inhibrx Biosciences Director Kimberly Manhard Revises Stock Option Grant Filing - Kalkine Media
Director at Inhibrx (NASDAQ: INBX) awarded 10,000 options - Stock Titan
Inhibrx (NASDAQ: INBX) director gets 10,000 options expiring 2036 - Stock Titan
Inhibrx (INBX) corrects director's 10,000-option grant - Stock Titan
Inhibrx (INBX) corrects 10,000-option grant to director - Stock Titan
Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock - Investing.com
Family trust of Inhibrx (INBX) director adds 5,000 shares at $100 - Stock Titan
Director’s trust sells 1,500 Inhibrx (INBX) shares - Stock Titan
Director’s trust at Inhibrx (NASDAQ: INBX) logs four 500-share stock sales - Stock Titan
Inhibrx (NASDAQ: INBX) director's trust files to sell 500 shares - Stock Titan
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - webull.com
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com South Africa
Director trust at Inhibrx (INBX) proposes $55.9K stock sale - Stock Titan
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com Australia
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com UK
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock - Investing.com
Inhibrx Biosciences Director Kimberly Manhard Sells 1,000 Shares via Revocable Trust in September 2026 - Kalkine Media
Director’s trust at Inhibrx Biosciences (INBX) sells 1,000 shares in two days - Stock Titan
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - simplywall.st
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - simplywall.st
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com South Africa
Director-linked trust plans $57.9K INBX stock sale - Stock Titan
Inhibrx, Eikon rise after insider buying - TradingView
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy By Investing.com - Investing.com Canada
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom (NASDAQ:INBX) - Seeking Alpha
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com Australia
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com Canada
Inhibrx (INBX) investor files notice to sell 500 shares - Stock Titan
Family trust tied to Inhibrx (INBX) director buys more stock in open market - Stock Titan
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data - TipRanks
Inhibrx (INBX) director buys 2,500 shares via family trust - Stock Titan
Inhibrx Biosciences (INBX) chief boosts stake with 25,000-share buy - Stock Titan
80% response in HPV+ head and neck cancer lifts Inhibrx (INBX) trial plans - Stock Titan
Why Inhibrx Biosciences (INBX) Stock Is Down Today - Quiver Quantitative
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inhibrx Biosciences Inc-Aktie (INBX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lappe Mark | Chief Executive Officer |
Sep 28 '26 |
Buy |
100.76 |
4,500 |
453,426 |
740,548 |
| Lappe Mark | Chief Executive Officer |
Sep 25 '26 |
Buy |
99.16 |
5,500 |
545,357 |
736,048 |
| Kayyem Jon Faiz | Director |
Sep 23 '26 |
Buy |
100.00 |
5,000 |
500,000 |
434,360 |
| Kayyem Jon Faiz | Director |
Sep 16 '26 |
Buy |
100.00 |
5,000 |
500,000 |
429,360 |
| MANHARD KIMBERLY | Director |
Sep 15 '26 |
Proposed Sale |
105.05 |
500 |
52,525 |
0 |
| MANHARD KIMBERLY | Director |
Sep 15 '26 |
Sale |
105.05 |
500 |
52,525 |
7,500 |
| MANHARD KIMBERLY | Director |
Sep 14 '26 |
Sale |
110.26 |
500 |
55,130 |
8,000 |
| MANHARD KIMBERLY | Director |
Sep 14 '26 |
Proposed Sale |
110.26 |
500 |
55,130 |
0 |
| MANHARD KIMBERLY | Director |
Sep 11 '26 |
Sale |
111.78 |
500 |
55,888 |
8,500 |
| MANHARD KIMBERLY | Director |
Sep 11 '26 |
Proposed Sale |
111.78 |
500 |
55,888 |
0 |
3.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):